e-ISSN: 2345-0592

### **Online issue**

Indexed in Index Copernicus

### **Medical Sciences**

Official website: www.medicsciences.com



### Fibroadenoma treatment strategies

### Justė Kazlauskaitė<sup>1</sup>, Mindaugas Kvietkauskas<sup>2</sup>

<sup>1</sup>Faculty of Medicine of Vilnius University, Vilnius, Lithuania

<sup>2</sup>Center of Abdominal and Oncological Surgery, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania

### Abstract

**Background**. Fibroadenoma is a very common benign tumor in young women. Surgery is the standard treatment for fibroadenomas. However, cosmetic changes after breast surgery cause psychological problems that impair patients' quality of life. For these reasons, nowadays it is very important to individualize the treatment of fibroadenomas using nonsurgical treatment methods.

Aim: to review feasible treatment methods for fibroadenoma and indications, with a focus on recent advancements.

**Methods.** A literature review was conducted in the PubMed database, using the keywords. "fibroadenoma", "fibroadenoma treatment", "fibroadenoma advancements", and "fibroadenoma treatment management". The date was from 2014 to 2024, and the study was limited to English-language publications (n = 47).

**Results**. Fibroadenomas, often managed with traditional surgical excision (500,000 surgeries/year worldwide), can also be observed due to their low malignancy risk (0.002 - 0.0125 %). Observation is suitable for non-growing, asymptomatic lumps, especially in patients under 35. Minimally invasive methods offer aesthetic and recovery advantages over surgery, but surgical excision remains common for larger or symptomatic fibroadenomas. Pharmacological treatments like Metformin show potential, but others, like Ormeloxifene, are less effective and have significant side effects.

**Conclusions**. The treatment of fibroadenomas depends on the size, symptoms, and patient preference. Small, nongrowing fibroadenomas usually require regular checkups, while larger, symptomatic, or growing tumors may need surgical resection or minimally invasive procedures. Minimally invasive approaches offer advantages in recovery, cosmetic outcome, and safety, and can save time, help avoid scars, and reduce surgical costs.

Keywords: fibroadenoma, fibroadenoma treatment, fibroadenoma advancements, fibroadenoma treatment management.

#### 1. Introduction

Fibroadenomas are benign breast tumors that are common among women aged 14-35 years. About 10 % of women worldwide will have fibroadenomas in their lifetime (1). As mentioned above, fibroadenomas are most common in women and very rare in men (2). Iatrogenic male fibroadenomas occur due to prostate carcinoma treatment and in male-to-male transgender people as a result of estrogen therapy (3). Of all breast biopsies fibroadenoma accounts for 30 to 75 % (4). The pathogenesis of fibroadenoma is not well-known. It is believed that fibroadenoma develops due to changes in hormone levels, obesity and family history (5). The connective tissues of the stroma and epithelium of fibroadenoma contain estrogen and progesterone receptors that can cause excessive growth of breast tissue. MED12 (the mediator complex subunit 12) gene also promotes the formation of fibroadenomas (1). Fibroadenoma in the family history can be an important risk factor for the development of fibroadenoma (6). It is usually unilateral, non-cancerous, and a painless breast tumor that resolves itself in approximately 60 % of all fibroadenoma cases and therefore is less common in post-menopausal women (7). For this reason, fibroadenomas are usually observed. Although the likelihood of malignancy is low (0.002 to 0.0125 %) (8), surgery is the standard treatment for fibroadenoma. However, cosmetic changes after breast surgery or permanent thoughts about the malignancy in observation often lead to psychological problems, which impair patients' quality of life (9). This article aims to review feasible treatment methods for fibroadenoma and indications, with a focus on recent advancements.

### 2. Methods

A literature review was conducted in the Medline (PubMed) database. The included data varied from 2014 to 2024. A detailed search, including the keywords "fibroadenoma", "fibroadenoma treatment", "fibroadenoma advancements", "fibroadenoma treatment management" has revealed a total of 276 articles. Records titles and abstracts limited to English language (n = 148). Full-text articles assessed for eligibility (n = 47).

### 3. Results

### 3.1. Treatment Strategies

Even though nowadays there is a diversity of fibroadenoma treatment options, the most common ones are traditional methods, for example, surgical excision (500,000 surgeries/year worldwide) and observation (8). The other treatment options for fibroadenoma are presented in **Error! Reference source not found.** (8,10,11). The goals of nonsurgical treatment of breast fibroadenoma are to stop lesion growth and reduce palpable mass while maintaining acceptable cosmetic results (12).

### 3.1.1. Observation

Removing the lump solves the problem, but surgery is not always needed and may have bad cosmetic outcomes as well as be a burden on the healthcare system, especially when some of these lumps disappear on their own (13). Fibroadenomas with no symptoms that are not growing rapidly and cause no cosmetic issues can be observed yearly by performing an ultrasound. However, if the patient is worried about observation and experiences anxiety about malignancy despite the low risk (less than 1%), removal of asymptomatic fibroadenomas may be considered. Indications for observation also include patients younger than 35 years old, sonographically typical fibroadenoma (14). It is recommended to perform clinical palpation and ultrasonography every 6 months. In patients whose disease is stable should be observed for 2 years, the observation interval may be extended to every 12 months (10).


Treatment methods	Indications		
Percutaneous ultrasound-guided	Visible on ultrasound. Confirmed histologically with core biopsy. Size		
cryoablation.	less than 4 cm. Lesion near the skin.		
Vacuum-assisted breast biopsy.	Smaller than 2-3 cm.		
Laser ablation.	Size less than 20 mm.		
Percutaneous microwave	Fibroadenomas > 2 cm. Adjacent to the areola.		
treatment.			
Radiofrequency-assisted excision.	Multiple fibroadenoma.		
High-intensity focused ultrasound.	Distance from the skin of $\leq 23$ mm to the posterior, $\geq 5$ mm from the		
	anterior border of the fibroadenoma, and $\geq 11$ mm from the focal point		
	of the ultrasound treatment. The chest wall must be $>1$ cm from the		
	posterior margin of the tumor.		
Pharmacological methods.	Multiple fibroadenomas.		

**Table 1.** Nonsurgical treatment and indications

### 3.1.2. Surgical excision

Fibroadenoma size varies from 2 to 3 cm. Although, masses can range from < 1 cm to greater than 10 cm. The ones that are greater than 5 cm require surgical excision. Usually, they are found in the upper-outer quadrant of the breast (15). Surgical excision indications are shown in Table 2 (16-18). Fibroadenomas can be removed using either local or general anesthesia (19). Surgical resections for various benign breast tumors leave a significant scar. The optimal incisions to minimize visible scarring are inframammary and circumareolar. The size and location of a fibroadenoma influence the choice of incision site (Figure 1) (15). Radial and directly extended incisions (Figure A, D) should not be used in conservative breast surgery (20). Areolar or periareolar incision (Figure B, C) is used for fibroadenomas near the areola, offering good access and cosmetic outcomes. Superior circumareolar incision (Figure B) is used if the lump is further away. Periareolar incision (Figure C) is suitable for patients with an areolar diameter > 3.5-5 cm, massto-areola distance < 5 cm, fibroadenoma < 3 cm, and age < 35. Contraindications include small areola, tumor > 5 cm, mass-to-areola distance > 6 cm, suspected malignancy, and age > 35 (21). With the periareolar technique, postoperative complications occurred faster (22). An inframammary incision (Figure E) is used if the lump is deep in the breast. This incision provides optimal tissue visualization and hides scars in the lower breast crease. It poses a low risk of breastfeeding issues and is suitable for fibroadenomas in the lower inner to lower outer breast quadrant (23). Axillary incision (Figure F):is used if the fibroadenoma is near the armpit. The surgeon may use an axillary incision to access it, resulting in less visible scarring on the breast but leaving a scar in the armpit (24). The choice of incision type depends on various factors, such as fibroadenoma location, size. the patient's preferences, or the surgeon's expertise. Nowadays, the requirements for a beautiful post-operative breast appearance are higher (25). It's essential to discuss these options with the surgeon to determine the most suitable approach for a specific case.

**Figure 1.** Incisions for removing lumps from the breast. A - superolaterial radial incision, B - superior circumareolar incision, C - periareolar incision, D - inferolateral radial incision. E - inframammary fold incision, F - axillary incision, G - other incision.



# 3.1.3. Percutaneous ultrasound-guided cryoablation

Cryoablation uses the cytotoxic effects of cold to create tumor necrosis (26). Cryoablation is a safe and effective nonsurgical treatment for breast fibroadenomas, with optimal response in tumors smaller than 2 cm. Ultrasound follow-up is recommended every 6 months for 2 years (27). Cryoablation causes little discomfort after the procedure and does not result in deformity. The results show that 75 % of lesions are no longer palpable after treatment at 1-year follow-up (16).

## 3.1.4. Vacuum-assisted percutaneous therapeutic excisional biopsy

Vacuum-assisted breast biopsy (VAB) is effective at excising smaller fibroadenomas (less than 15 mm), but it is less successful with larger lesions (28). Complete excision effectiveness has been reported to be in a range from 70 to 100 % (29). Clinicians and patients favor VAB for its efficacy in lesion removal, improved cosmetic outcomes, and suitability as a day-care procedure (30).

### 3.1.5. Percutaneous interstitial laser ablation

Percutaneous interstitial laser ablation (ILA) uses a portable diode laser to generate heat in tissues. The photothermal effect can be followed by magnetic resonance thermometry or by internal and accessory temperature monitors placed into the tissue (31). ILA relies on imaging for guidance, prioritizing demarcated lesions no larger than 20 mm (32). Major side effects include skin burns, and the most serious complication is pneumothorax (33). The treatment is done under local anesthesia with minimal pain and discomfort. It is aesthetically superior to lumpectomy (32).

### 3.1.6. Percutaneous microwave treatment

Percutaneous microwave treatment (MWA) is a promising thermal ablation technique (34). MWA offers better cosmetic results, less pain, and fewer complications, but surgery is still better because the recurrence rate is lower (35). Some studies showed that MVA is a very efficient treatment for fibroadenomas > 2 cm, without damage to normal tissue (36). The results of a study of 122 patients showed that cosmetic results after treatment with MWA were excellent (90.2 %) (34).

### 3.1.7. Radiofrequency-assisted excision

Radiofrequency-assisted excision (RFA) uses lowfrequency radio waves and causes localized coagulative tissue necrosis (26). RFA works by heating water molecules and causing coagulation. The treatment goal for RFA is to ablate the whole lesion plus a 1 cm tissue rim to between 50–100° C for 9 minutes (31). The procedure is well tolerated by patients and is associated with minimal complications (37). RFA has advantages in the treatment of multiple fibroadenomas. Conducted studies show that RFA can become the most suitable method for treating fibroadenomas due to such advantages as a high rate of complete ablation, little damage to the surrounding tissues, quick recovery after the procedure, and a cosmetic result that satisfies patients (8,38).

### 3.1.8. High-intensity focused ultrasound

High-intensity focused ultrasound (HIFU) is an ablation technique that uses an ultrasound beam to pass through the tissue as a high-frequency pressure wave that passes through the tissue causing protein denaturation and necrosis. Surrounding tissues are preserved (39). HIFU surgery is an effective and safe noninvasive alternative technique for the treatment of breast fibroadenoma (40). According to the studies, although the HIFU method is safe, but in some cases, coagulation necrosis of cells was found after this treatment (41). The efficacy and safety of HIFU therapy for breast fibroadenomas larger than 3 cm are unclear (42). Recurrence occurs in approximately 4 % of cases treated this way and is more likely in patients with multiple lesions, larger lesions, and hematoma at surgery. HIFU has shown promising results (16).

#### 3.1.9. Pharmacological methods

Although fibroadenomas are relatively benign, they can cause significant psychological distress. Patients about often worry misdiagnosis, potential malignancy, and fear when touching the lump, which are common concerns with conservative treatment (43). Metformin, an anti-hyperglycemic agent, is being studied for various medical conditions. Metformin exhibits effects on breast cancer cells. Given fibroadenoma's estrogendependent and proliferative nature, along with Metformin's low incidence of side effects, metformin might have therapeutic potential for treating fibroadenoma (44). Ormeloxifene is a new nonsteroidal drug that produces estrogen agonist and strong antagonist activity and is used to treat fibroadenoma. However multiple studies have reported that Ormeloxifene was not effective in fibroadenoma treatment and had side effects, such as hot flashes, irregular menstruation, headaches, depression, thromboembolic events, eye disease, leg cramps, endometrial hyperplasia, and more (45).

## **3.2.** Evaluation of treatment methods for fibroadenoma

Recent systematic reviews indicate that minimally invasive methods for breast treatment offer significant advantages over traditional surgery in terms of patient recovery, aesthetic outcomes, and overall safety. Ardila C. M. et al. found that these techniques result in better aesthetic results, less postoperative morbidity, and improved clinical outcomes compared to conventional surgery (46). According to Zhang W. et al. study, the MWA technique is found to be an effective, safe, and promising alternative to traditional surgical methods (47). In most cases, fibroadenomas require no intervention as they naturally diminish with time (1). However, for some reasons explained in Table 2, surgery might be advisable. Despite this, many women opt against surgery due to the benign nature of these lesions, which pose no enduring risk of malignancy. Usually, women do not feel comfortable being observed for psychological reasons. Surgical procedures can rarely result in complications, such as wound infections, scar formation, and breast deformity. According to Peek et al., minimally invasive, time-consuming ablative techniques are MWA, cryoablation and HIFU. Minimally invasive and time-efficient are LA and RFA (39). Minimally invasive methods of treating fibroadenomas vary greatly depending on the equipment available at the hospital. It is difficult to evaluate the effectiveness of each of them.

Comparative studies are needed to compare ablation methods and determine which one is most promising. However, ongoing research into the causes of fibroadenomas may reveal new therapeutic targets that could be used in drug development. And finally, the most important part patient involvement in treatment. Applying the analyzed treatment methods in practice can offer the patient more treatment alternatives.

Table 2.	Surgical	excision	indications
----------	----------	----------	-------------

Surgical excision indications		
Mass greater than 5 cm.		
Rapid grow.		
Nonmobile, hard, enlarging, tender (can be		
smaller than 5 cm).		
Fixed to the overlying skin or nipple areolar		
complex.		
Associated with axillary or supraclavicular		
lymphadenopathy.		
The patient is experiencing anxiety because of		
the mass.		

Breast asymmetry.

### 4. Conclusion

According to this review of the literature, the treatment of fibroadenomas depends on the indications, psychological patient status and preferences of the patient. For small, stable fibroadenomas, regular surveillance is usually sufficient, but if the tumor is large or symptoms are severe, surgical resection or minimally invasive procedures such as ultrasound biopsy or laser ablation may be necessary. Compared to traditional surgical methods, minimally invasive fibroadenoma resection methods are better due to faster recovery of patients, smaller postoperative scars and complications, and better psychological well-being

of patients. It is necessary to pay attention to medical treatment, because of the possibility to save time, avoid postoperative scars, and reduce the costs of surgical operations.

### **Conflict of Interest**

The authors have declared that no competing interests exist.

### Funding

The authors have no funding to report.

### References

 Ajmal M, Khan M, Van Fossen K. Breast Fibroadenoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 6, 2022.

2. Morikawa H, Nobuoka M, Amitani M, Shimizu T, Ohno K, Ono M, Oba T, Ito T, Kanai T, Maeno K, Uehara T, Ito KI. Fibroadenoma in a young male breast: A case report and review of the literature. Clin Case Reports. 2021;9(11):1–5.

3. Agarwal P, Kohli G. Fibroadenoma in the male breast: Truth or Myth? Turkish J Surg. 2016;32(3):208–11.

4. Kovatcheva R, Guglielmina JN, Abehsera M, Boulanger L, Laurent N, Poncelet E. Ultrasoundguided high-intensity focused ultrasound treatment of breast fibroadenoma-a multicenter experience. J Ther Ultrasound. 2015;3(1):1–8.

5. Zhu L, Zeng X, Jiang S, Ruan S, Ma H, Li Y, Ye C, Dong J.. Prevalence of breast fibroadenoma in healthy physical examination population in Guangdong province of China: A cross-sectional study. BMJ Open. 2022;12(6):1–7.

6. Ramala SR, Chandak S, Chandak MS, Annareddy S. A Comprehensive Review of Breast Fibroadenoma: Correlating Clinical and Pathological Findings. Cureus. 2023;15(12).

7. Li J, Humphreys K, Ho PJ, Eriksson M, Darai-Ramqvist E, Lindström LS, Hall P, Czene K. Family History, Reproductive, and Lifestyle Risk Factors for Fibroadenoma and Breast Cancer. JNCI Cancer Spectr. 2018;2(3):1–7.

 Salati SA. Breast fibroadenomas: a review in the light of current literature. Polish J Surg. 2020;93(1):40–8.

9. Li Z, Yue X, Pan F, Yang L, Xiao Y, Mu D, Liu H, Chen M, Yin H, Huang H, Wang Z, Zhang C. A Comparison of Quality of Life, Cosmesis and Cost-Utility of Open Surgery, Vacuum-Assisted Breast Biopsy and High Intensity Focused Ultrasound for Breast Fibroadenoma. Acad Radiol. 2024;1–10.

 Peng Y, Xie F, Zhao Y, Wang S. Clinical practice guideline for breast fibroadenoma: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021. Chin Med J (Engl). 2021;134(9):1014–6.

 Bhimani C. Fibroadenoma: From Imaging Evaluation to Treatment Background and Epidemiology. J Am Osteopat Coll Radiol. 2018;8(2).

12. Klinger M, Vinci V, Giannasi S, Bandi V, Veronesi A, Maione L, Catania B, Lisa A, Cornegliani G, Giaccone M, et al. The Periareolar Approach: All Seasons Technique for Multiple Breast Conditions. Plast Reconstr Surg - Glob Open. 2021;9(7): E3693.

13. Sperber F, Blank A, Metser U, Flusser G, Klausner JM, Lev-Chelouche D. Diagnosis and treatment of breast fibroadenomas by ultrasound-guided vacuum-assisted biopsy. Arch Surg 2003 Jul;138(7)796-800.

 Soltanian H, Lee M. Breast fibroadenomas in adolescents: current perspectives. Adolesc Health Med Ther. 2015;159.

15. Cerrato F, Labow BI. Diagnosis and management of fibroadenomas in the adolescent breast. Semin Plast Surg. 2013;27(1):23–5.

16. Kopkash K, Yao K. The surgeon's guide to fibroadenomas. Ann Breast Surg. 2020;4(7):25–25.

17. Meng X, Yamanouchi K, Kuba S, Sakimura C, Morita M, Matsuguma K, Kanetaka K, Takatsuki M, Abe K, Eguchi S. Giant fibroadenoma of the breast: A rare case in a mature woman. Int J Surg Case Rep. 2019; 63:36–9.

Naraynsingh V, Pran L, Islam S, Cawich S.
 The 'Saw Tooth' operation for giant fibroadenomas.
 Int J Surg Case Rep. 2017; 41:304–6.

19. Kim H, Shim J, Kim I. Surgical excision of the breast giant fibroadenoma under regional anesthesia by Pecs II and internal intercostal plane block: a case report and brief technical description: a case report. Korean J Anesthesiol. 2017;70(1):77-80.

20. Chirappapha P, Petit JY, Rietjens M, De Lorenzi F, Garusi C, Martella S, Barbieri B, Gottardi A, Andrea M, Giuseppe L, Hamza A, Lohsiriwat V. sparing mastectomy: Does Nipple breast factor related morphological necrotic to complications? Plast Reconstr Surg. 2014 Feb 7;2(1): e99.

 Nisar W, Zarin M, Muslim M, Mushtaq M,
 Khan S. Fibroadenoma excision through periareolar incision versus an overlying incision. Pakistan J Surg. 2013;29(3):165–8.

22. Farooqi NB, Naseer S, Atari HAH, Balouch V, Muzaffar Ali Joyo R. Excision of Fibroadenoma with an Upper Incision Compared To the Periareolar Incision. Pakistan J Med Heal Sci. 2022;16(3):1169–70.

23. Yang JD, Lee J, Lee JS, Kim EK, Park CS, Park HY. Aesthetic scar-less mastectomy and breast reconstruction. J Breast Cancer. 2021;24(1):22–33.

24. Gonzalez, M., & Pimpalwar A. Transaxillary Subcutaneouscopic Excision of Fibroadenoma of the Breast in Children: The Covert Scar Approach. J Laparoendosc Adv Surg Tech Part A, 2016; 26(2), 157–160.

25. Kong X, Chen X, Jiang L, Ma T, Han B, Yang Q. Periareolar incision for the management of

benign breast tumors. Oncol Lett. 2016;12(5):3259–63.

26. Mactier M, McIntosh SA, Sharma N. Minimally invasive treatment of early, good prognosis breast cancer—is this feasible? Br J Radiol. 2024;(February):1–8.

27. Sheth M, Lodhi U, Chen B, Park Y, McElligott S. Initial Institutional Experience With Cryoablation Therapy for Breast Fibroadenomas: Technique, Molecular Science, and Post-Therapy Imaging Follow-up. J Ultrasound Med. 2019;38(10):2769–76.

Thurley P, Evans A, Hamilton L, James J,
 Wilson R. Patient satisfaction and efficacy of vacuum-assisted excision biopsy of fibroadenomas.
 Clin Radiol. 2009 Apr 1;64(4):381–5.

29. Salazar JP, Miranda I, De Torres J, Rus MN, Espinosa-Bravo M, Esgueva A, et al. Percutaneous ultrasound-guided vacuum-assisted excision of benign breast lesions: A learning curve to assess outcomes. Br J Radiol. 2019;92(1094).

30. Rupa R, Kushvaha S. Vacuum-Assisted Excision, Scarless Solution for Fibroadenoma Breast-A Single-Center Experience. Indian J Radiol Imaging. 2021 Nov 1;31(4):844-849.

31. Sag AA, Maybody M, Comstock C, Solomon SB. Percutaneous image-guided ablation of breast tumors: An overview. Semin Intervent Radiol. 2014;31(2):193–202.

32. Dowlatshahi K, Wadhwani S, Alvarado R, Valadez C, Dieschbourg J. Short communication interstitial laser therapy of breast fibroadenomas with 6 and 8 year follow-up. Breast J. 2010;16(1):73–6.

33. Kerbage Y, Betrouni N, Collinet P, Azaïs H, Mordon S, Dewalle-Vignion AS, et al. Laser interstitial thermotherapy application for breast surgery: Current situation and new trends. Breast 2017; 33:145–52.

34. Yu J, Chen BH, Zhang J, Han ZY, Wu H,

Huang Y, Mu MJ, Liang P. Ultrasound guided percutaneous microwave ablation of benign breast lesions. Oncotarget. 2017 May 23;8(45):79376-79386.

35. Saad H. A Comparison of Rotational Adenomammectomy, Surgery, and Ultrasound-Guided Microwave Ablation for benign breast mass. Int J Heal Sci. 2023;0(0):0–0.

36. Cui R, Wu H, Xu J, Han Z, Zhang J, Li Q, Dou J, Yu J, Liang Pl. Volume reduction for  $\geq 2$  cm benign breast lesions after ultrasound-guided microwave ablation with a minimum 12-month follow-up. Int J Hyperth. 2021;38(1):341–8.

37. Fine RE, Staren ED. Percutaneous radiofrequency-assisted excision of fibroadenomas.Am J Surg. 2006;192(4):545–7.

38. Li P, Xiao-Yin T, Cui D, Chi JC, Wang Z, Wang T, Qi XX, Zhai B. Evaluation of the safety and efficacy of percutaneous radiofrequency ablation for treating multiple breast fibroadenoma. J cancer Res Ther 12(Supplement), C138–C142. 2016;14(7):1525–34.

39. Peek MCL, Douek M. Ablative techniques for the treatment of benign and malignant breast tumours. J Ther Ultrasound. 2017 Jul 3; 5:18.

40. Cavallo Marincola, B., Pediconi, F., Anzidei, M., Miglio, E., Di Mare, L., Telesca, M., Mancini, M., D'Amati, G., Monti, M., Catalano, C., Napoli A. High-intensity focused ultrasound in breast pathology: non-invasive treatment of benign and malignant lesions. Expert Rev Med devices, 12(2), 191–199. 2015;

41. Xiao Y, Liang M, Chen M, Li Z, Xia T, Yue X, Yin H, Yang H, Huang H, Wang Z, Zhang C. Evaluating the learning curve of high intensity focus ultrasound for breast fibroadenoma by CUSUM analysis: a multi-center study. Int J Hyperthermia. 2022;39(1):1238-1244.

42. Liang M, Zhang Z, Zhang C, Chen R, Xiao Y, Li Z, Li T, Liu Y, Ling L, Xie H, et al. Feasibility

and efficacy of ultrasound-guided high-intensity focused ultrasound of breast fibroadenoma. Int J Hyperth. 2023;40(1).

43. Coriaty Nelson Z, Ray RM, Gao DL, Thomas DB. Risk factors for fibroadenoma in a cohort of female textile workers in Shanghai, China. Am J Epidemiol. 2002 Oct 1;156(7):599-605.

44. Alipour S, Abedi M, Saberi A, Maleki-Hajiagha A, Faiz F, Shahsavari S, Eslami B. Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial. BMC Endocr Disord. 2021 Aug 20;21(1):169.

45. Agrawal K, Silodia A, Yadav SK, Sharma DB, Sharma D. Double blind randomized controlled trial of efficacy of ormeloxifene for the treatment of fibroadenoma (The FIBROCENT study). World J Surg. 2024;(November 2023):1–6.

46. Ardila CM, González-Arroyave D, Vivares-Builes AM. A Systematic Review of Randomized Clinical Trials Evaluating the Efficacy of Minimally Invasive Surgery for Soft Tissue Management: Aesthetics, Postoperative Morbidity, and Clinical Results. Med. 2023;59(5).

47. Zhang W, Jin ZQ, Baikpour M, Li JM, Zhang H, Liang T, Pan XM, He W. Clinical application of ultrasound-guided percutaneous microwave ablation for benign breast lesions: A prospective study. BMC Cancer. 2019;19(1):1–10.